Abstract
The in vitro activity of pazufloxacin (PZFX), a new quinolone, was compared with those of tosufloxacin (TFLX), ciprofloxacin (CPFX), ofloxacin (OFLX) and norfloxacin (NFLX) against a variety of anaerobic bacteria and small number of facultative anaerobic bacteria.
PZFX had broad spectrum against gram-positive and gram-negative reference strains of anaerobes, inhibiting many anaerobic bacterial strains at 3.13μg/ml or less. However, PZFX showed weak activity against some ofPeptostreptococcus spp. and Clostridium spp., and Bacteroides fragilis group organisms. No influence of inoculum size upon antimicrobial activity was seen in PZFX. In the study against fresh clinical isotes, generally PZFX was less active than TFLX, as active as CPFX and OFLX, and more active than NFLX. PZFX was as active against imipenem-resistant B. fragilis group organisms as against imipenem-sensitive B. fragilis group organisms but not active against OFLX-resistant B. fragilis. These results suggested that PZFX treatment may be effective against infections with many of Peptostreptococcus spp., Prevotella spp. and Porphyromonas spp., and some of Clostridium spp. but not B. fragilis group organisms and Prevotella bivia.
